|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:advocates_for
|
required
|
|
gptkbp:analysis
|
intention-to-treat
|
|
gptkbp:analyzes
|
HE R2-positive breast cancer
Dr. Javier Cortés
|
|
gptkbp:business_model
|
gptkb:battle
|
|
gptkbp:clinical_trial
|
gptkb:III
gptkb:KATHERINE_trial
NC T01120184
|
|
gptkbp:collaborations
|
gptkb:European_Society_for_Medical_Oncology
|
|
gptkbp:committee
|
gptkb:battle
|
|
gptkbp:completed
|
gptkb:2018
|
|
gptkbp:criteria
|
HE R2-positive status
prior treatment with T-D M1
|
|
gptkbp:events
|
at least 2 years
|
|
gptkbp:field_of_study
|
oncology
|
|
gptkbp:focuses_on
|
gptkb:healthcare_organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MARIANNE trial
|
|
gptkbp:is_compared_to
|
trastuzumab emtansine
trastuzumab plus chemotherapy
|
|
gptkbp:is_protected_by
|
parallel assignment
|
|
gptkbp:is_studied_in
|
multicenter
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:launched
|
gptkb:2012
|
|
gptkbp:located_in
|
gptkb:Europe
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:members
|
trastuzumab plus chemotherapy
|
|
gptkbp:notable_work
|
T-D M1 is effective
|
|
gptkbp:participants
|
overall survival
progression-free survival
|
|
gptkbp:population
|
adult women
|
|
gptkbp:products
|
trastuzumab emtansine
|
|
gptkbp:provides_information_on
|
gptkb:battle
gptkb:stock_market_index
|
|
gptkbp:published_year
|
gptkb:2019
|
|
gptkbp:receives_funding_from
|
gptkb:Genentech
|
|
gptkbp:recorded_by
|
gptkb:battle
|
|
gptkbp:recruitment
|
completed
|
|
gptkbp:research
|
published
interventional
|
|
gptkbp:result
|
gptkb:The_Lancet
improved outcomes
efficacy of trastuzumab emtansine
|
|
gptkbp:safety_features
|
acceptable
|
|
gptkbp:side_effect
|
gptkb:battle
|
|
gptkbp:significance
|
p<0.05
|
|
gptkbp:sponsor
|
gptkb:Roche
|
|
gptkbp:student_enrollment
|
approximately 1100 patients
|
|
gptkbp:treatment
|
three
|
|
gptkbp:vision
|
gptkb:battle
|
|
gptkbp:year
|
gptkb:2016
gptkb:2018
|
|
gptkbp:bfsParent
|
gptkb:Trastuzumab_emtansine
|
|
gptkbp:bfsLayer
|
6
|